4D Molecular Therapeutics FDMT Proceeds From Issuance Of Common Stock Under Stock Purchase Agreement
Proceeds From Issuance Of Common Stock Under Stock Purchase Agreement at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept fdmt:ProceedsFromIssuanceOfCommonStockUnderStockPurchaseAgreement.
The official record: 4D Molecular Therapeutics’s 10-K, filed March 18, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's proceeds from issuance of common stock under stock purchase agreement.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's proceeds from issuance of common stock under stock purchase agreement?
- 4D Molecular Therapeutics (FDMT) reported proceeds from issuance of common stock under stock purchase agreement of $1.88M in Q4 2025.
- What does proceeds from issuance of common stock under stock purchase agreement mean?
- Reflects the cash proceeds received from the sale of common stock to investors or strategic partners pursuant to a formal stock purchase agreement. This metric highlights the company's ability to raise external equity capital to fund operations, research, and development. It is a primary indicator of the company's access to capital markets.